Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TQB 2102

Next Previous
Drug Profile

TQB 2102

Alternative Names: HER2 dual-antibody-drug conjugate - Chia Tai Tianqing Pharmaceutical Group; TQB-2102

Latest Information Update: 03 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chia Tai Tianqing Pharmaceutical Group
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gynaecological cancer; HER2 negative breast cancer; HER2 positive breast cancer; Non-small cell lung cancer
  • Phase I/II Biliary cancer; Breast cancer
  • Phase I Cancer

Most Recent Events

  • 09 Jun 2025 Chia Tai Tianqing Pharmaceutical plans a phase-III trial for HER2- positive breast cancer (Neoadjuvant therapy) in China (IV, injection) in August 2025 (NCT07043725)
  • 06 Jun 2025 Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical plans a phase III trial for HER2 positive breast cancer(Recurrent, Metastatic disease, Second-line therapy or greater, Late-stage disease) in China (IV, Infusion) in June 2025 (NCT07008976)
  • 04 Jun 2025 Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical plans a phase III trial for HER2 positive breast cancer(Recurrent, Metastatic disease, Second-line therapy or greater) in China (IV, Infusion) in August 2025 (NCT07003074)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top